CGS 26393

Drug Profile

CGS 26393

Latest Information Update: 18 Feb 2000

Price : $50

At a glance

  • Originator Novartis
  • Class Antihypertensives; Phosphonic acids
  • Mechanism of Action Endopeptidase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Hypertension

Most Recent Events

  • 18 Feb 2000 No-Development-Reported for Hypertension in USA (PO)
  • 25 Jan 1996 A preclinical study has been added to the pharmacokinetics section
  • 17 Oct 1995 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top